Helix Data Analytics is an independent research and investment firm dedicated to the life sciences. We pair deep scientific diligence with patient, data-driven capital to back the breakthroughs that matter.
Helix Data Analytics sits at the intersection of biotechnology research and capital allocation. We were founded on a simple conviction: the best investment decisions in life sciences come from understanding the underlying biology, clinical data, and translational risk — not market sentiment.
Free from the conflicts of larger institutions, we deliver candid, evidence-based research and deploy capital with the patience that real science demands.
Diligence grounded in molecular mechanism and clinical evidence.
Conviction-weighted, long-horizon allocation across the value chain.
No banking conflicts. Our only incentive is being right.
We work alongside founders and LPs as long-term partners.
We evaluate every company through three connected disciplines — the science, the business, and the statistics — so conviction is never built on a single dimension.
We start with the biology — dissecting the mechanism of action to understand exactly how a drug, device, or platform actually works.
We pressure-test the commercial thesis — company valuation, total addressable market, penetration potential, and the competitive landscape.
We interrogate the data itself — the statistics behind every top-line readout — to understand what the clinical results actually mean.
We move at the speed of data — not headlines. Every position and recommendation is backed by primary research, structured analysis, and a clear thesis.
Managing Director
With a deep foundation in rigorous fundamental research, asset valuation, and corporate capital structures, Richard establishes the quantitative frameworks that guide the firm’s research operations.
His background bridges the gap between complex technological value and institutional investment execution, focusing on deep analytical discovery where conventional consensus analysis falls short.
A representative selection of public companies we research and track — spanning oncology, immunology, gene therapy, and beyond.
For informational purposes only. Logos and trademarks are the property of their respective owners and do not imply endorsement, affiliation, or a recommendation to buy or sell any security.
Whether you're a founder seeking a research-led partner or an investor looking for genuine independence, we'd love to hear from you.
